Tadalafil Dosage and Administration Guidelines for Women

Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in

6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status.

Make an informed decision about tadalafil

Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point. In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor. Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required.

For the initial PHIRST study, the local institutional review boards or independent ethics committees approved the protocol, and written consent was obtained from all patients.3

What should I know about storage and disposal of this medication?

Multivariate linear regression and Cox proportional hazards models were built for 6MWD and TCW, respectively. Women were subdivided by age as a surrogate for menopausal status. The linear trend test and the log-rank test were performed on change in 6MWD and TCW by age. For tadalafil-treated patients, a significant difference in change in 6MWD by sex (mean: 48.6 m for males vs. 34.7 m for females; P = 0.01) was found, but it was not significant in multivariate analysis (P = 0.08). Subjects were at least 12 years of age and had symptomatic PAH (the youngest male was 19 years old; the youngest female was 14 years old).

Does tadalafil work for low libido in women?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If cheap tadalafil you find any errors in the information, please contact us.

US Brand Name

Pulmonary arterial hypertension (PAH) is a female-predominant disease, but there are little data on treatment response by sex and menopausal status. In this retrospective analysis of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) randomized clinical trial, we assessed treatment response between the sexes by examining change in 6-minute walk distance (6MWD) and time to clinical worsening (TCW). We examined the effect of menopausal status on the same treatment measures. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in the PHIRST study cohort of 340 subjects (264 females, 76 males). A univariate analysis was used to assess the effect of sex on change in 6MWD and TCW. Subjects exposed to anorexigens or given a diagnosis of connective tissue disease, HIV infection, congenital pulmonary shunts, or idiopathic PAH were included in this study.

Data Availability

There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement. A significant sex- or age-dependent effect on TCW was not present. In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a paucity of literature investigating the effect of menopause on response to PAH treatment. Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH. The hemodynamic criteria for PAH included mean pulmonary arterial pressure of ≥25 mmHg, pulmonary arterial wedge pressure of ≤15 mmHg, and pulmomary vascular resistance of ≥3 Wood units.

• Tadalafil's mechanism targets blood vessels to promote dilation.
• It may help women with blood flow-related sexual problems.
• The drug's research status means limited official approvals.
• Female studies explore impacts on sexual satisfaction and arousal.
• Its off-label use is increasing with ongoing research.
• Tadalafil could improve genital flushing and sensitivity.
• Women with cardiac risk factors should avoid tadalafil.
• Clinical trials are testing daily versus as-needed dosing.
• User reports vary, and more evidence is necessary.

Patients with a 6MWD of <150 or >450 m were excluded.

Patients treated with intravenous epoprostenol, inhaled or intravenous iloprost, or subcutaneous or intravenous treprostinil were excluded.

• Tadalafil may supplement other treatments for female sexual health.
• Its effects on vaginal lubrication are being studied.
• Use in women should be monitored carefully for adverse effects.
• It could provide a new option for women unresponsive to other therapies.
• The drug enhances vascular dilation in female genitalia.
• Long-term safety data in women are lacking.
• Its role in clinical practice remains experimental.
• Dose flexibility allows tailored treatment plans.
• Women interested should seek professional guidance.

Patients taking a maximum dose of bosentan (125 mg) twice daily for a minimum of 12 weeks at the time of screening continued to receive bosentan in addition to the study medicine.

New Competition for Viagra®

Hormone levels—especially estrogen and testosterone—can fluctuate during this time. If your symptoms sound familiar, it may not just be a blood flow issue. Hormonal shifts could be playing a central role. Before jumping to conclusions, it's worth using a free AI-powered symptom checker specifically for Peri-/Post-Menopausal Symptoms to better understand whether hormonal changes might be at the root of what you're experiencing. Understanding the root cause is key before considering medications like tadalafil.

Publisher’s Note

Before starting tadalafil, your doctor may explore: Changing antidepressants if sexual side effects are present Helpful if emotional or relationship factors are involved Sexual dysfunction can sometimes signal underlying health conditions, including: In some cases, reduced genital blood flow may mirror reduced blood flow elsewhere in the body. That's why sexual health changes shouldn't be ignored. If you're considering tadalafil, bring these questions to your appointment: Is tadalafil safe given my health history? Could hormones be contributing to my symptoms? Are there alternative treatments I should try first? In total, 405 subjects (317 females, 88 males) were enrolled in a 16-week, double-blind, double-dummy, placebo-controlled multicenter study.

What should I do if I forget to take a dose?

What side effects should I watch for? How will we monitor whether it's working? Your doctor may recommend blood tests, a cardiovascular check, or a hormone panel before prescribing anything. Tadalafil may offer benefits for some women aged 30–45 who struggle with physical aspects of sexual arousal. It is not FDA-approved for female sexual dysfunction It does not address emotional or hormonal causes It must be prescribed and monitored by a doctor If you're noticing changes in sexual function, don't ignore them—but don't panic either.

Table 1.

Many causes are manageable once properly identified. If you suspect hormonal shifts may be involved, take a few minutes to complete a free symptom checker for Peri-/Post-Menopausal Symptoms to gain clarity on what might be happening with your body. Most importantly, speak to a doctor about any symptoms that are persistent, worsening, or potentially serious. Sexual health is part of your overall health—and you deserve thoughtful, evidence-based care. If something feels off, trust your instincts and get medical guidance. Subjects were randomized into groups receiving placebo or 2.5, 10, 20, or 40 mg of tadalafil once daily. 6MWD was recorded before and after 16 weeks of treatment with tadalafil or placebo in a cohort of 340 subjects (264 females, 76 males).3 Clinical worsening was defined as

• Tadalafil belongs to PDE5 inhibitors, aiding blood flow.
• It is sometimes called "female Viagra" in popular media.
• Tadalafil's duration of action is approximately 36 hours.
• Female users should consult healthcare providers before use.
• Tadalafil may interact with other medications like nitrates.
• Existing studies show mixed results on tadalafil’s efficacy in women.
• It may be more effective when combined with therapy.
• Not recommended for women with certain cardiovascular conditions.
• Female use of tadalafil is still experimental and investigational.

death, lung or heart-lung transplantation, atrial septostomy, hospitalization due to worsening PAH, initiation of new PAH-approved therapy, or worsening World Health Organization (WHO) functional class over the 16 weeks.

Rights and permissions

Safety and Efficacy of Phosphodiesterase-5 Inhibitors in the Treatment of Female Sexual Dysfunction: A Systematic Review and Meta-analysis of Randomized Clinical Trials. * Basile A, Giammò A, Gangi FM, Rindone L, Iannello S, Piloni V. Pharmacological treatment of female sexual dysfunction: an update. * Cui Y, Li J, Yu Q, Chen X, Yang X, Li J. Phosphodiesterase-5 inhibitors in female sexual dysfunction: a systematic review and meta-analysis.

More common

* Worsley R, Corazza O, Al Kadhi O, Patel V. Female Sexual Dysfunction: A Review of the Current Literature. We would love to help them too. We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.